ArticleRegenerative therapy2026
Evaluation of the efficacy of conditioned medium derived from quality- and quantity-cultured peripheral blood mononuclear cells for erectile dysfunction.
Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neurogenic erectile dysfunction (ED) due to cavernous nerve injury (CNI) leads to irreversible apoptosis of the cavernosal smooth muscle and fibrosis. These structural changes are often refractory to conventional treatments. Serum-free Methods: Corpus cavernosum smooth muscle cells (CCSMCs) isolated from murine penile tissue were assessed for proliferation and resistance to apoptosis following MNCQQ-CM treatment. Angiogenic capacity was evaluated through proliferation and tube formation assays using human umbilical vein endothelial cells (HUVECs). MNCQQ-CM composition was analyzed using enzyme-linked immunosorbent assay (ELISA). Bilateral CNI was induced in male rats, followed by intracavernosal injection of MNCQQ-CM, and subsequent evaluation of erectile function and histology. Results: MNCQQ-CM significantly enhanced CCSMCs proliferation. Under oxidative stress, it reduced CCSMCs apoptosis. Moreover, MNCQQ-CM promoted HUVEC proliferation and tube formation, demonstrating its angiogenic potential. The presence of vascular endothelial growth factor and interleukin-10 in MNCQQ-CM was confirmed by ELISA. In CNI rats, MNCQQ-CM significantly improved erectile function and increased the smooth muscle/collagen ratio. Conclusions: MNCQQ-CM demonstrates therapeutic efficacy in ED through multiple mechanisms, including angiogenesis, promotion of CCSMCs proliferation, and anti-fibrotic activity. The synergistic interaction of cytokines in MNCQQ-CM contributes to ED improvement. Given its rapid and minimally invasive production process, MNCQQ-CM holds substantial promise as a novel therapeutic agent for neurogenic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.